Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.
Open Access
- 1 December 1993
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 92 (6) , 2756-2760
- https://doi.org/10.1172/jci116893
Abstract
The effects of plasminogen activator inhibitor-1 (PAI-1) gene inactivation on hemostasis, thrombosis and thrombolysis were studied in homozygous PAI-1-deficient (PAI-1-/-) mice, generated by homologous recombination in D3 embryonic stem cells. Diluted (10-fold) whole blood clots from PAI-1-/- and from PAI-1 wild type (PAI-1+/+) mice underwent limited but significantly different (P < 0.001) spontaneous lysis within 3 h (6 +/- 1 vs 3 +/- 1%, respectively). A 25-microliters 125I-fibrin-labeled normal murine plasma clot, injected into a jugular vein, was lysed for 47 +/- 5, 66 +/- 3, and 87 +/- 7% within 8 h in PAI-1+/+, heterozygous PAI-1-deficient (PAI-1+/-), and PAI-1-/- mice, respectively (P = 0.002 for PAI-1+/+ vs PAI-1-/- mice). Corresponding values after pretreatment with 0.5 mg/kg endotoxin in PAI-1+/+ and PAI-1-/- mice, were 35 +/- 5 and 91 +/- 3% within 4 h, respectively (P < 0.001). 11 out of 26 PAI-1+/+ but only 1 out of 25 PAI-1-/- mice developed venous thrombosis (P = 0.004) within 6 d after injection of 10 or 50 micrograms endotoxin in the footpad. Spontaneous bleeding or delayed rebleeding could not be documented in PAI-1-/- mice after partial amputation of the tail or of the caecum. Thus, disruption of the PAI-1 gene in mice appears to induce a mild hyperfibrinolytic state and a greater resistance to venous thrombosis but not to impair hemostasis.Keywords
This publication has 27 references indexed in Scilit:
- On the role of coagulation and fibrinolysis in atherosclerosisAnnals of Epidemiology, 1992
- Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.Journal of Clinical Investigation, 1989
- Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.Heart, 1988
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide.The Journal of Immunology, 1987
- Plasminogen activator inhibitors.1987
- Plasminogen activator inhibitor in the blood of patients with coronary artery disease.BMJ, 1985
- Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.Journal of Clinical Investigation, 1985
- Increased PA-Inhibitor Levels in the Postoperative Period – No Cause-Effect Relation with Increased CortisolThrombosis and Haemostasis, 1985
- The Measurement of Fibrinolysis in the RatThrombosis and Haemostasis, 1971